Effect of double platinum agents, combination of miriplatin-transarterial oily chemoembolization and cisplatin-hepatic arterial infusion chemotherapy, in patients with hepatocellular carcinoma: Report of two cases

Figure 1 Images of Case 1. Contrast-enhanced ultrasonography. A: The vascular arterial phase; B: The Kupffer phase; EOB-MRI; C: T1-weighted MRI image; D: The arterial phase; E: The portal phase; F: The hepatobiliary phase; G and H: Angiography. EOB-MRI: Gd-EOB-DTPA-enhanced magnetic resonance imaging.

Figure 2 The representative dynamic contrast-enhanced computed tomography images of case 1 before and after eight times of combination therapy. A-C: White arrows indicate tumors before the combination therapy; D-F: White arrows with dotted line indicate the tumor disappearance after eight times of combination therapy.

Figure 3 Changes in alpha-fetoprotein, albumin and prothrombin time after eight combination therapy. None of them did show a significant change after each session. PT: Prothrombin time; AFP: Alpha-fetoprotein.

Figure 4 Images of Case 2. Contrast-enhanced ultrasonography: A: The vascular arterial phase; B: The Kupffer phase; EOB-MRI: C: T1-weighted MRI image; D: The arterial phase; E: The hepatobiliary phase of EOB-MRI; F: Several tumorous lesions in the liver besides S5 lesion in the arterial phase of EOB-MRI study; Angiography: G. EOB-MRI: Gd-EOB-DTPA-enhanced magnetic resonance imaging.

Figure 5 The representative dynamic contrast-enhanced computed tomography images of case 2 before and after three times of combination therapy and radiofrequency ablation. A and B: White arrows indicate tumors before treatment; C and D: White arrows with dotted line indicate tumors disappearance or reduction after three times of combination therapy and radiofrequency ablation.

Figure 6 Changes in alpha-fetoprotein, albumin and prothrombin time after three combination therapy and radiofrequency ablation. None of them did show a significant change after each treatment. PT: Prothrombin time; AFP: Alpha-fetoprotein.